GlaxoSmithKline plans a radical shift in patent policy that seeks to encourage copies of its medicines in poor countries, widening access and possibly diminishing calls for compulsory licenses or other challenges based on price.
A new contract research organization has risen out of the flames of Glaxo's former Canadian vaccines unit as it sets up shop in the pharma company's old Laval facility.
Through its recent purchases and divestitures, GlaxoSmithKline has placed an increased emphasis on its vaccines business worldwide. Now, it'll look to build its vaccine offerings in one of the world's most populous countries, with an executive this week saying the British pharma giant aims to launch in India multiple combination vaccines in the coming months.
GlaxoSmithKline CEO Andrew Witty may be heading for the door next year--but he's still touting the strategy he put in place there, and he believes it won't be following him out.
In particular, I would like to correct what I believe is a misinterpretation of something that GSK CEO Andrew Witty stated at a healthcare conference in 2013.
GlaxoSmithKline is collaborating with Germany's Miltenyi Biotec on the "industrialization" of cell and gene therapy, as part of the Big Pharma's effort to harness the technique for the development of therapies to treat cancer and rare diseases.
It's official: GlaxoSmithKline CEO Andrew Witty is moving on. At the helm of the U.K.-based drugmaker since 2008, Witty will step down in March 2017, clearing the way for a new captain to chart a new course.
GlaxoSmithKline and Miltenyi Biotec have signed an R&D; cell and gene therapy pact that will see the British Big Pharma delve deeper into the brave new world of CAR-T-based oncology treatments. This brave new world will not however feature its leader, Andrew Witty, who announced his retirement today.
In a twist on the traditional smoking cessation model, GlaxoSmithKline is pairing with 2morrow's SmartQuit app to supply patches to smokers who have already completed the app plan.
Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders.